Prognostic implications of the immunophenotype in biphenotypic acute leukemia

References

• Greaves M F. Differentiation-linked leukemogenesis in lymphocytes. Science 1986; 234: 697–704
   PubMed Web of Science ®Google Scholar
• Altman A J. Clinical features and biological implications of acute mixed lineage (hybrid) leukemias. Am J Pediatr Hematol Oncol 1990; 12: 123–133
   PubMedGoogle Scholar
• Bene M C, Castoldi G, Knapp W, Ludwig W D, Matutes E, Orfao A, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995; 9: 1783–1786
   PubMed Web of Science ®Google Scholar
• Carbonell F, Swansbury J, Min T, Matutes E, Farahat N, Buccheri V, et al. Cytogenetic findings in acute biphenotypic leukaemia. Leukemia 1996; 10: 1283–1287
   PubMed Web of Science ®Google Scholar
• Hurwitz C A, Mirro J, Jr. Mixed-lineage leukemia and asynchronous antigen expression. Hematol Oncol Clin North Am 1990; 4: 767–794
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Hirsch-Ginsberg C, Yee G, Huh Y, Freireich E J, Stass S. Mixed-lineage leukemia revisited: acute lymphocytic leukemia with myeloperoxidase-positive blasts by electron microscopy. Blood 1990; 76: 808–813
   PubMed Web of Science ®Google Scholar
• Killick S, Matutes E, Powles R L, Hamblin M, Swansbury J, Treleaven J G, et al. Outcome of biphenotypic acute leukemia. Haematologica 1999; 84: 699–706
   PubMed Web of Science ®Google Scholar
• Legrand O, Perrot J Y, Simonin G, Baudard M, Cadiou M, Blanc C, et al. Adult biphenotypic acute leukaemia: an entity with poor prognosis which is related to unfavourable cytogenetics and P-glycoprotein over-expression. Brit J Haematol 1998; 100: 147–155
   PubMed Web of Science ®Google Scholar
• Matutes E, Morilla R, Farahat N, Carbonell F, Swansbury J, Dyer M, et al. Definition of acute biphenotypic leukemia. Haematologica 1997; 82: 64–66
   PubMed Web of Science ®Google Scholar
• Mirro J, Zipf T F, Pui C H, Kitchingman G, Williams D, Melvin S, et al. Acute mixed lineage leukemia: clinicopathologic correlations and prognostic significance. Blood 1985; 66: 1115–1123
   PubMed Web of Science ®Google Scholar
• Owaidah T M, Al Beihany A, Iqbal M A, Elkum N, Roberts G T. Cytogenetics, molecular and ultrastructural characteristics of biphenotypic acute leukemia identified by the EGIL scoring system. Leukemia 2006; 20: 620–626
   PubMed Web of Science ®Google Scholar
• Sulak L E, Clare C N, Morale B A, Hansen K L, Montiel M M. Biphenotypic acute leukemia in adults. Am J Clin Pathol 1990; 94: 54–58
   PubMed Web of Science ®Google Scholar
• Greaves M F, Chan L C, Furley A J, Watt S M, Molgaard H V. Lineage promiscuity in hemopoietic differentiation and leukemia. Blood 1986; 67: 1–11
   PubMed Web of Science ®Google Scholar
• Smith L J, Curtis J E, Messner H A, Senn J S, Furthmayr H, McCulloch E A. Lineage infidelity in acute leukemia. Blood 1983; 61: 1138–1145
   PubMed Web of Science ®Google Scholar
• The value of c-kit in the diagnosis of biphenotypic acute leukemia. EGIL (European Group for the Immunological Classification of Leukaemias). Leukemia 1998; 12: 2038
   PubMedGoogle Scholar
• Hanson C A, Abaza M, Sheldon S, Ross C W, Schnitzer B, Stoolman L M. Acute biphenotypic leukaemia: immunophenotypic and cytogenetic analysis. Brit J Haematol 1993; 84: 49–60
   PubMed Web of Science ®Google Scholar
• Thalhammer-Scherrer R, Mitterbauer G, Simonitsch I, Jaeger U, Lechner K, Schneider B, et al. The immunophenotype of 325 adult acute leukemias: relationship to morphologic and molecular classification and proposal for a minimal screening program highly predictive for lineage discrimination. Am J Clin Pathol 2002; 117: 380–389
   PubMed Web of Science ®Google Scholar
• Cross A H, Goorha R M, Nuss R, Behm F G, Murphy S B, Kalwinsky D K, et al. Acute myeloid leukemia with T-lymphoid features: a distinct biologic and clinical entity. Blood 1988; 72: 579–587
   PubMed Web of Science ®Google Scholar
• Ball E D, Davis R B, Griffin J D, Mayer R J, Davey F R, Arthur D C, et al. Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood 1991; 77: 2242–2250
   PubMed Web of Science ®Google Scholar
• Ferrara F, Del Vecchio L. Clinical relevance of acute mixed-lineage leukemia. Blood 1992; 79: 2799–2800
   PubMed Web of Science ®Google Scholar
• Kita K, Miwa H, Nakase K, Kawakami K, Kobayashi T, Shirakawa S, et al. Clinical importance of CD7 expression in acute myelocytic leukemia. The Japan Cooperative Group of Leukemia/Lymphoma. Blood 1993; 81: 2399–2405
   PubMed Web of Science ®Google Scholar
• Kornblau S M, Thall P, Huh Y O, Estey E, Andreeff M. Analysis of CD7 expression in acute myelogenous leukemia: martingale residual plots combined with ‘optimal’ cutpoint analysis reveals absence of prognostic significance. Leukemia 1995; 9: 1735–1741
   PubMed Web of Science ®Google Scholar
• Saxena A, Sheridan D P, Card R T, McPeek A M, Mewdell C C, Skinnider L F. Biologic and clinical significance of CD7 expression in acute myeloid leukemia. Am J Hematol 1998; 58: 278–284
   PubMed Web of Science ®Google Scholar
• Yumura-Yagi K, Hara J, Kurahashi H, Okamura J, Koizumi S, Toyoda Y, et al. Clinical significance of CD7-positive stem cell leukemia. A distinct subtype of mixed lineage leukemia. Cancer 1991; 68: 2273–2280
   PubMed Web of Science ®Google Scholar
• Cheson B D, Bennett J M, Kopecky K J, Buchner T, Willman C L, Estey E H, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642–4649
   PubMed Web of Science ®Google Scholar
• Brunning R D, Matutes E, Borowitz M, Flandrin G, Head D, Vardiman J, . Acute leukaemias of ambiguous lineage. WHO Tumours of Haematopoietic and Lymphoid Tissues, E S Jaffe, N L Harris, H Stein, J W Vardiman, et al. IARC, Lyon 2001; 106–107
   Google Scholar
• Tien H F, Wang C H. CD7 positive hematopoietic progenitors and acute myeloid leukemia and other minimally differentiated leukemia. Leuk Lymphoma 1998; 31: 93–98
   PubMed Web of Science ®Google Scholar
• Bain B J, Barnett D, Linch D, Matutes E, Reilly J T. Revised guideline on immunophenotyping in acute leukaemias and chronic lymphoproliferative disorders. Clin Lab Haematol 2002; 24: 1–13
   PubMedGoogle Scholar
• Lee K H, Lee J H, Choi S J, Lee J H, Seol M, Lee Y S, et al. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2005; 19: 1509–1516
   PubMed Web of Science ®Google Scholar
• Faderl S, Thomas D A, O'Brien S, Garcia-Manero G, Kantarjian H M, Giles F J, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003; 101: 3413–3415
   PubMed Web of Science ®Google Scholar
• Laporte J P, Isnard F, Garderet L, Fouillard L, Gorin N C. Remission of adult acute lymphocytic leukaemia with alemtuzumab. Leukemia 2004; 18: 1557–1558
   Google Scholar
• Tibes R, Keating M J, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, et al. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer 2006; 106: 2645–2651
   PubMed Web of Science ®Google Scholar